Hamish A. Innes, Scott A. McDonald, John F. Dillon, Sam Allen, Peter C. Hayes, David Goldberg, Peter R. Mills, Stephen T. Barclay, David Wilks, Heather Valerio, Ray Fox, Diptendu Bhattacharyya, Nicholas Kennedy, Judith Morris, Andrew Fraser, Adrian J. Stanley, Peter Bramley, Sharon J. Hutchinson – 26 February 2015 – Sustained viral response (SVR) is the optimal outcome of hepatitis C virus (HCV) therapy, yet more detailed data are required to confirm its clinical value. Individuals receiving treatment in 1996‐2011 were identified using the Scottish HCV clinical database.

Zheng Zhang, Jian‐Gao Fan, Fu‐Sheng Wang – 26 February 2015

Emmanuel Gonzales, Brigitte Grosse, Brice Schuller, Anne Davit‐Spraul, Filomena Conti, Catherine Guettier, Doris Cassio, Emmanuel Jacquemin – 26 February 2015 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4‐phenylbutyrate (4‐PB), have been shown to partially correct mistrafficking.

Surakit Pungpapong, Bashar Aqel, Michael Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy E. Chervenak, Kymberly D. Watt, Hugo E. Vargas, Andrew P. Keaveny – 26 February 2015 – Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with minimal adverse events in non–liver transplant (LT) patients with hepatitis C virus (HCV) genotype 1 infection.

Tian Yang, Han Zhang, Wan Yee Lau, Feng Shen, Meng‐Chao Wu – 26 February 2015

Emmanuel Gonzales, Brigitte Grosse, Brice Schuller, Anne Davit‐Spraul, Filomena Conti, Catherine Guettier, Doris Cassio, Emmanuel Jacquemin – 26 February 2015 – Progressive familial intrahepatic cholestasis type 2 (PFIC2) is a result of mutations in ABCB11 encoding bile salt export pump (BSEP), the canalicular bile salt export pump of hepatocyte. In some PFIC2 patients with missense mutations, BSEP is not detected at the canaliculus owing to mistrafficking of BSEP mutants. In vitro, chaperone drugs, such as 4‐phenylbutyrate (4‐PB), have been shown to partially correct mistrafficking.

Surakit Pungpapong, Bashar Aqel, Michael Leise, K. Tuesday Werner, Jennifer L. Murphy, Tanisha M. Henry, Kristen Ryland, Amy E. Chervenak, Kymberly D. Watt, Hugo E. Vargas, Andrew P. Keaveny – 26 February 2015 – Treatment with an all‐oral interferon‐free antiviral regimen using simeprevir and sofosbuvir with or without ribavirin (RBV) for 12 weeks resulted in high sustained virologic response (SVR) rates along with minimal adverse events in non–liver transplant (LT) patients with hepatitis C virus (HCV) genotype 1 infection.

Jian‐Hong Fang, Hui‐Chao Zhou, Chong Zhang, Li‐Ru Shang, Lei Zhang, Jing Xu, Limin Zheng, Yunfei Yuan, Rong‐Ping Guo, Wei‐Hua Jia, Jing‐Ping Yun, Min‐Shan Chen, Yaojun Zhang, Shi‐Mei Zhuang – 24 February 2015 – Early metastasis is responsible for frequent relapse and high mortality of hepatocellular carcinoma (HCC), but its underlying mechanisms remain unclear. Epithelial–mesenchymal transition (EMT) has been considered a key event in metastasis.

Richard Moreau, Emmanuel Weiss – 24 February 2015

Qilin Gu, Zongbin Cui – 24 February 2015